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Cannabis use is associated with cardiovascular adverse effects ranging from arrhythmias to sudden 
cardiac death. The exact mechanism of action behind these activities is unknown. The aim of our 
work was to study the effect of cannabidiol (CBD), tetrahydrocannabinol and 11‑nor‑9‑carboxy‑
tetrahydrocannabinol on cellular cardiac electrophysiological properties including ECG parameters, 
action potentials, hERG and  IKr ion channels in HEK cell line and in rabbit and guinea pig cardiac 
preparations. CBD increased action potential duration in rabbit and guinea pig right ventricular 
papillary muscle at lower concentrations (1 µM, 2.5 µM and 5 µM) but did not significantly change it at 
10 µM. CBD at high concentration (10 µM) decreased inward late sodium and L‑type calcium currents 
as well. CBD inhibited hERG potassium channels with an  IC50 value of 2.07 µM at room temperature 
and delayed rectifier potassium current with 6.5 µM at 37 °C, respectively. The frequency corrected QT 
interval  (QTc) was significantly lengthened in anaesthetized guinea pig without significantly changing 
other ECG parameters. Although the  IC50 value of CBD was higher than literary  Cmax values after CBD 
smoking and oral intake, our results raise the possibility that hERG and potassium channel inhibition 
might have a role in the possible proarrhythmic adverse effects of cannabinoids in situations where 
metabolism of CBD impaired and/or the repolarization reserve is weakened.
Cannabis is the most abused hallucinogenic drug, with an estimated of 150 million consumers  worldwide1. 
With the increasingly widespread use of e-cigarettes, the number of people inhaling cannabinoids might even 
be higher. Moreover, the use of cannabis products for medicinal purposes is increasing globally. The interest for 
the use of cannabis and cannabis-derived products started following the discovery of the cannabinoid system in 
the human brain and body and the subsequent reports on new findings on biological activities of cannabinoids 
on central nervous system and immune functioning. Currently, there are cannabis-based medicines on the 
market with well-defined medicinal indications, including treatment of nausea and vomiting associated with 
chemotherapy, anorexia, pain related to cancer, spasticity and pain associated with multiple sclerosis, Dravet 
and Lennox-Gastaut syndromes. These medicines contain known amounts of CBD and/or THC in pure form 
or as standardized herbal  extract2. Besides, the use of CBD-containing products (CBD oil) is very widespread 
with several, clinically unsupported indications. The intake of cannabinoids, especially CBD, which is enriched 
in several products, may be higher in case of the consumption of CBD oils than in case of smoking cannabis.
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The cardiovascular adverse effects of cannabinoid use have been reported in several case reports, and range 
from arrhythmias to myocardial infarction and sudden  death3. According to the results of a cohort study, mari-
juana smokers have a 4.8-fold increased risk of developing acute myocardial infarction during the first hour of 
 exposure4. However, other data do not support the association between cannabis use and cardiovascular  events5. 
The most comprehensive study assessed data for 316,397 cannabis users and 20,499,215 non-users, and found 
that cannabis use is an independent predictor of heart  failure1. Although the exact mechanisms explaining these 
observations are unknown, the activities of cannabinoids exerted via the G protein-coupled cannabinoid recep-
tors are supposed to be of key importance. In addition, several studies described the proarrhythmic potency 
of cannabinoids ranging from ventricular arrhythmias to sudden cardiac  death6–8. However, the exact associa-
tion and mechanism of these arrhythmias remain  unknown7. Besides, certain voltage-gated ion channels like 
cardiac sodium,  calcium9 and Kv4.3  channels10 might also be related to the reported cardiovascular effects of 
cannabinoids, but the exact role of these channels has not been studied yet in detail. One of the most important 
ion channels in cardiac repolarization is the rapid delayed rectifier potassium channel  (IKr), which plays a critical 
role in cardiac repolarization, having a pore-forming subunit encoded by the hERG (the human Ether-à-go-
go-Related Gene) gene. Inhibitors of  IKr (also called hERG ion channel) are known to lengthen the QT interval, 
and hence might induce life-threatening arrhythmias. Therefore, formal drug development requires an early 
screening of whether the potential drug candidates bear any activities on the hERG  channels11. However, drug 
effects on cardiac repolarization cannot be accurately estimated by measuring hERG channel currents  alone12, 
since drug responses on native  IKr channel and action potential can be different from those measured in hERG.
In the present study cannabidiol (CBD), tetrahydrocannabinol (THC) and 11-nor-9-carboxy-tetrahydro-
cannabinol (11-nor-9-carboxy-THC), the main metabolite of THC was assessed for their effects on the hERG 
channels in an in vitro assay. CBD and THC are the major components of cannabis products for medicinal and 
recreational use, respectively, and since the latter is quickly metabolized to 11-nor-9-carboxy-THC, these three 
compounds were chosen to be tested in vitro.
Therefore, the aim of our work was to study the in vitro and in vivo effects of CBD a major cannabinoid on 
cardiac ventricular action potential, on ECG parameters, on the hERG and on other native cardiac transmem-
brane channels to provide experimental data for the elucidation of their possible adverse cardiac electrophysi-
ological effects.
Results
As our first test shown in Fig. 1, CBD was found to be an inhibitor of the hERG potassium channel with inter-
mediate potency represented by  IC50 values of 2.07 ± 0.12 µM (n = 6) at room temperature. The  IC50 values for the 
inhibition elicited by THC were higher (10.30 ± 0.55 µM, n = 6 at room temperature). 11-Nor-9-carboxy-THC 
exhibited only a marginal effect  (IC50 = 65.40 ± 3.82 µM, n = 4 at room temperature).
The cardiac cellular electrophysiological effect of the most potent cannabis compound CBD was further 
studied on various transmembrane ionic currents by the whole-cell configuration of the patch clamp technique 
in native rabbit ventricular myocytes and on action potentials in rabbit and guinea pig right ventricular papil-
lary muscle by the conventional microelectrode technique and on in vivo ECG studies in anaesthetized guinea 
pigs. Figure 2 shows that CBD lengthens action potential duration  (APD90) slightly but significantly at 1 µM and 
at 2.5 µM. This latter effect depended on the stimulation frequency and vanished at slow pacing rate. At high 
10 µM concentration CBD exerted variable effect on repolarization including minimal or no change, shorten-
ing and lengthening of  APD90 resulting statistically not significant alteration of APD. At 1 and 2.5 µM CBD 
caused triangulation in some experiments but not in others reflected as not significant change in  APD90–APD25. 
Similar results were obtained in guinea pig papillary muscles where 2.5 and 5 µM CBD increased  APD90 from 
186.2 ± 6.1 ms and 179.9 ± 6.0 ms to 192.2 ± 6.8 and to 191.5 ± 8.9 ms, respectively (p < 0.05, n = 5).
In anaesthetized in vivo guinea-pig experiments intravenous administration of 0.3 mg/kg and 1 mg/kg CBD 
lengthened QTc and QRS intervals in a statistically significant manner without significantly changing other 
ECG parameter (Fig. 3).
Whole-cell patch clamp experiments on rabbit native cardiac ventricular myocytes revealed significant and 
voltage-dependent inhibition of the rapid delayed rectifier potassium current  (IKr) (Figs. 4a,c) with an estimated 
 IC50 value of 6.5 µM after a 20 mV 1 s long test pulse and measured at −40 mV as deactivating tail current 
(Fig. 4b).
The observation that high (10 µM) concentration of CBD did not further lengthened APD prompted us to 
study the possible effect of CBD on inward L-type  Ca2+  (ICaL) and late inward  Na+  (INaL) currents. As Fig. 5a,b 
show, 10 µM CBD decreased  ICaL significantly and in a frequency-dependent manner. In addition, 10 µM CBD 
also significantly inhibited  INaL by 41.5% at −20 mV (Fig. 5c,d).
Discussion
The main result of our study is that CBD lengthens repolarization at low and does not change it statistically 
significant manner at higher concentrations. This effect on repolarization in rabbit papillary muscle can be best 
explained by the multiple ion channel effects of CBD. Accordingly, at lower concentrations (1, 2.5 and 5 µM)  IKr 
depression results in lengthening of  APD90, which is counterbalanced by inward  Ca2+ and  Na+ currents inhibition 
at 10 µM. Similar effect was earlier described by quinidine, an antiarrhythmic drug, with reported proarrhythmic 
 property13,14. The  IKr inhibition by CBD, which is consistent with the hERG blockade, is most probably a direct 
effect on the channel but the effect of CBD on  INaL and on  ICaL can be either direct or receptor mediated, as well. 
It needs more research to be established.
The higher  IC50 values of THC and 11-nor-9-carboxy-THC than that of CBD in hERG current measurement 
in our study does not necessarily mean that CBD is more potent in other type of experiments since potency can 
3Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:16079  | https://doi.org/10.1038/s41598-020-73165-2
www.nature.com/scientificreports/
Figure 1.  Effect of CBD on hERG current at room temperature. (a) Representative current curves obtained 
from HEK-hERG cells treated with 0.3, 1, 3, and 10 µM CBD. The currents were recorded using the voltage 
protocol shown at the top of the panel after 3–5 min acute superfusion of the drugs without washout. (b) Time-
course of the hERG peak tail current amplitude upon the application of different concentrations of CBD. (c) 
Dose–response curves of CBD’s inhibitory activity on the hERG channel.
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differ from a target to  another12. However, in our study due to technical limitations we focused our investigations 
to examine the effects of CBD in more depth.
Some previous study with cannabinoids showed effects on various transmembrane ion channels such as 
inward  sodium9,15, inward  calcium9, outward transient  current16 and human Kv1.5 and Kv4.3  channels10,17. Our 
results in rabbit ventricular myocytes are in good agreement with those reported by Al Kury et al. on inward 
calcium and sodium currents in rat ventricular  myocytes9. In a previous study hERG channel inhibition and 
QT lengthening were also reported in anaesthetized  rats18 by a synthetic cannabinoid compound (JWH-030). 
This synthetic cannabinoid compound differs from those investigated by us and inhibited hERG channel with a 
relatively high  IC50 (88.36 µM). In addition, in rat ventricle hERG/IKr seems not so important to control repolari-
zation than Kv4.2 and Kv1.5 channels. Therefore, the cannabinoid-evoked QT changes in rat most likely can be 
attributed to Kv1.5 and Kv4.2 rather than hERG channel inhibition. It is worth to note that in the same  study18 
a cannabinoid derivate JWH-030 did not change APD in low but shortened it at high (30 µM) concentration. 
Therefore, the results of our study is in partial agreement with these earlier reports and the differences are best 
explained by different preparations, chemical differences of the studied compounds and experimental conditions.
The  IC50 values reported here together with the  Cmax values of CBD allow the assessment of cardiovascular 
risks of this compound. Based on the comparison of hERG or  IKr activity, cardiac action potential duration, and 
QT prolongation against QT effects and reports of arrhythmogenic (torsade de pointes) potential of 100 drugs, 
a margin of at least 30-fold between hERG  IC50 and  Cmax was proposed to an acceptable degree of safety from 
 arrhythmogenesis19. According to human pharmacokinetic data, the  Cmax values for CBD might reach 0.35 µM 
and 0.58 µM after CBD smoking (19.2 mg) and oral intake (400 mg),  respectively20. In our experiments CBD 
had an inhibitory effect on both the hERG channel and  IKr activity, with an  IC50 value higher than literary  Cmax 
values in patients. Considering the  IC50 values for  Ikr and hERG channel inhibition in our experiments (6.5 and 
2.07 µM, respectively), the ratios of  IC50 and  Cmax values are in the range of 3.57–18.57. This safety margin (below 
30) suggests a potential proarrhythmic risk in human setting. However, previous clinical reports documented no 
significant QT and  QTc prolongation in patients after CBD  administration21. Also, in another study it was found 
that long term Sativex (CBD + THC) treatment evoked T wave changes only 1 out of 146  patients22. This might be 
explained by the effects of CBD on other ion channels than hERG and  IKr.(eg.  ICaL and  INaL). However, in patients 
who have slower drug elimination due to certain diseases or in case of concurrent use of medicines inhibiting the 
metabolism of CBD, higher  Cmax values may develop and the risk of arrhythmia might be  increased23. Moreo-
ver, when co-administered with pharmacological agents affecting cardiac repolarization, as well as in certain 
Figure 2.  Effect of CBD after 30–50 min acute superfusion of the drug without washout on action potentials 
recorded from rabbit right ventricular papillary muscle at 37 °C. (a) The cycle length-dependent effect of 2.5 µM 
CBD on the duration of action potentials  (APD90). Bar diagrams (b) indicates the effects of 1 µM, 2.5 µM 
and 10 µM CBD on the action potential duration during steady-state at 1000 ms cycle length. Original action 
potential traces are shown on (c) recorded at 1000 ms cycle length in control conditions and in the presence of 
1 µM, 2.5 µM and 10 µM CBD.
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pathophysiological conditions such as hypokalaemia, or diseases like LQT syndrome, HCM, diabetes mellitus 
or heart failure where cardiac repolarization reserve or drug metabolism is impaired, CBD may have an addi-
tive effect, further increasing the proarrhythmic risk and the possibility of sudden cardiac death. Such additive 
Figure 3.  The volume conducted electrocardiogram (ECG lead II) signals in regular sinus rhythm in 
a pentobarbital anaesthetized (30 mg/kg i.p. bolus injection) guinea pig at three different time points 
indicated with dashed arrows: 1. drug-free baseline, value determined from 40 consecutive beats before drug 
administration; 2. value determined from 40 consecutive beats 15 min after the 0.3 mg/kg intravenously (iv) 
administered cannabidiol (CBD) by 2 min bolus; 3. value determined from 40 consecutive beats 15 min after 
the 1 mg/kg iv administered CBD by 2 min bolus. RR interval: the time elapsed between two successive R-waves 
of the QRS signal on the ECG. HR heart rate, QT interval the time from the start of the Q wave to the end 
of the T wave, QTc interval heart rate corrected QT interval, calculated with a correction method described 
 earlier27,28, QRS interval the time from the onset to the end of the QRS complex. Table shows the mean ± SE 
values of the ECG intervals at three different time points. Changes in mean scores over three time points were 
compared using the repeated measures ANOVA with Bonferroni correction. *p < 0.05 was taken as indicative of 
a statistically significant difference between values.
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effect was reported in both in  experiments24 and in  patients25. The cardiovascular effects of CBD may only partly 
be interpreted on its effects on hERG and  IKr ion channels, the cardiovascular safety of this compound may be 
influenced by its activities on other ion channels. Further studies are needed to assess the effects of other can-
nabinoids as well, and the in vivo relevance of these results, with special focus on the benefit-risk assessment of 
products with different cannabinoid content.
Methods
The hERG channel current was measured by planar technology in HEK 293 cell line by the whole-cell configura-
tion using an automated patch clamp system (Patchliner, Nanion Technologies GmbH., Munich, Germany) at 
room temperature as described  previously12. The following solutions were used during automated patch-clamp 
recording (compositions in mM): internal solution: KCl 50, NaCl 10, KF 60, EGTA 20, HEPES 10, pH 7.2 (KOH); 
external solution: NaCl 140, KCl 4, glucose-monohydrate 5,  MgCl2 1,  CaCl2 3, HEPES 10, pH 7.4 (NaOH). 
The voltage protocol for hERG ion channel started with a short (100 ms) −40 mV step to establish the baseline 
region. A depolarizing step was applied to the test potential of 20 mV for 3 s, and then the cell was repolarized 
to −40 mV (1 s) to evoke outward tail current. The peak tail current was corrected the leak current defined dur-
ing the first period to −40 mV. Holding potential was −80 mV. The pulse frequency was approximately 0.1 Hz. 
Recording started in external solution. After this control period, increasing concentrations of the test compound 
were applied, in order to record a complete concentration–response curve.
The action potential measurements were carried out in rabbit and guinea pig right ventricular papillary 
muscles by the conventional microelectrode techniques at 37 °C as described in detail  earlier12,26. Isolated muscle 
preparations obtained from the right ventricle were individually mounted in a tissue chamber while superfused 
with oxygenated modified Locke’s solution containing (in mM): NaCl 128.3, KCl 4,  CaCl2 1.8,  MgCl2 0.42, 
Figure 4.  Effect of CBD after 3–5 min acute superfusion of the drug without washout on the rapid delayed 
rectifier potassium current  (IKr) in rabbit left ventricular myocytes at 37 °C. Current–voltage curves show the 
inhibition of  IKr by 2.5 µM CBD (a). (b) Displays CBD concentration–response curve indicating an estimated 
 IC50 value of 6.5 µM for  IKr blockade. Original  IKr current traces are shown on (c) in control conditions and in 
the presence of 2.5 µM, 5 µM and 10 µM CBD recorded from rabbit left ventricular myocytes after a 1 s long 
pulse to 20 mV test potential with pulsing cycle length of 20 s.  IKr deactivating tail current was measured at 
−40 mV. The vertical axis on the left side of the panels shows the absolute current level. The dashed lines refer to 
the baseline for  IKr tail current level after the test pulse at −40 mV. The arrows indicate the amplitudes of the  IKr 
tail currents.
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 NaHCO3 21.4 and glucose 10 (pH 7.35–7.4) and stimulated through a pair of platinum electrodes with constant 
cycle length of 1000 ms. In case of cycle length-dependent measurements stimulation with different constant 
cycle lengths ranging from 300 to 5000 ms were also applied. Transmembrane potentials were recorded using 
conventional glass microelectrodes, filled with 3 M KCl and having tip resistances of 5–20 MΩ, connected to 
the input of a high impedance electrometer (Experimetria, type 309, Budapest, Hungary). The analog action 
potential signals were digitized with analogue-to-digital converters (ADA 3300, Real Time Devices Inc., State 
College, PA, USA) under software control (APES home-made software).
Transmembrane ion currents in native rabbit ventricular myocytes were measured by the whole-cell con-
figuration of the patch clamp technique at 37 °C (Axopatch 200B, Molecular Devices Inc., Sunnyvale, CA, USA) 
as described in detail  earlier12. Rapid delayed rectifier potassium current  (IKr), was recorded in HEPES-buffered 
Tyrode’s solution containing (in mM) NaCl 144,  NaH2PO4 0.33, KCl 4.0,  CaCl2 1.8,  MgCl2 0.53, glucose 5.5 and 
HEPES 5.0, at pH of 7.4. The composition of the pipette solution (in mM) was the following: KOH 110, KCl 
40,  K2ATP 5,  MgCl2 5, EGTA 5, and HEPES 10 (pH was adjusted to 7.2 by aspartic acid). 1 µM nisoldipine and 
0.5 µM HMR-1556 (the selective blocker of the slow delayed rectifier  K+ current—IKs) were added to the exter-
nal solution to eliminate  ICaL and  IKs, respectively.  IKr was determined as tail current at −40 mV after the end of 
1 s long depolarizing pulses ranging from −30 to +50 mV with pulsing cycle length of 20 s. The L-type calcium 
current  (ICaL) was recorded in HEPES-buffered Tyrode’s solution supplemented with 3 mM 4-aminopyridine. A 
special solution was used to fill the micropipettes (composition in mM: CsCl 125, TEACl 20, MgATP 5, EGTA 10, 
HEPES 10, pH was adjusted to 7.2 by CsOH).  ICaL current was evoked by 400 ms long depolarizing voltage pulses 
to various test potentials ranging from −35 to +55 mV with pulsing cycle length of 5 s. The holding potential was 
−80 mV. A short prepulse to −40 mV served to inactivate  Na+ current. The sodium current was activated by 2 s 
long depolarizing voltage pulses to −20 mV from the holding potential of −120 mV with pulsing cycle length of 
5 s. After 5–7 min incubation with CBD the external solution was replaced by that containing 20 µM TTX. TTX 
at this concentration completely blocks the late sodium current  (INaL). The external solution was HEPES-buffered 
Tyrode’s solution supplemented with 1 µM nisoldipine, 0.5 µM HMR-1556 and 0.1 µM dofetilide in order to 
block  ICaL,  IKs and  IKr currents. The composition of the pipette solution (in mM) was: KOH 110, KCl 40,  K2ATP 
5,  MgCl2 5, EGTA 5, HEPES 10 (pH was adjusted to 7.2 by aspartic acid).
Figure 5.  Effect of CBD after 3–5 min acute superfusion of the drug without washout on L-type calcium  (ICaL) 
and on the late sodium  (INaL) currents in rabbit left ventricular myocytes at 37 °C. On (a) current–voltage 
curves show the inhibition of  ICaL by 10 µM CBD at 5000 ms (left) and at 500 ms (right) cycle lengths. Original 
 ICaL current traces are shown on (b) in control conditions and in the presence of 10 µM CBD recorded from 
rabbit left ventricular myocytes at 5000 ms (left) and at 500 ms (right) cycle lengths at 0 mV test potential. TTX 
sensitive current  (INaL) traces (c) and a bar diagram (d) show the inhibition of  INaL by 10 µM CBD measured at 
−20 mV in rabbit left ventricular myocytes.
8Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:16079  | https://doi.org/10.1038/s41598-020-73165-2
www.nature.com/scientificreports/
ECG recordings were taken from adult guinea-pigs of both sexes (600–800 g) anaesthetized by intraperitoneal 
30 mg/kg pentobarbital and I–III leads were recorded after 15 min of cumulative intravenous administration of 
CBD into the jugular  vein27.
Statistics. All data are expressed as means ± SEM. Statistical analysis was performed with Student’s t test for 
paired data. The results were considered statistically significant when p was < 0.05.
Animal ethics statement. All experiments performed in rabbit and guinea pig ventricular preparations 
were carried out in compliance with the Guide for the Care and Use of Laboratory Animals (USA NIH pub-
lication NO 85-23, revised 1996) and conformed to the Directive 2010/63/EU of the European Parliament. 
The protocols have been approved by the Ethical Committee for the Protection of Animals in Research of the 
University of Szeged, Szeged, Hungary (approval number: I-74-24-2017) and by the Department of Animal 
Health and Food Control of the Ministry of Agriculture and Rural Development (authority approval number 
XIII/3331/2017).
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